PMID- 22447950
OWN - NLM
STAT- MEDLINE
DCOM- 20121119
LR  - 20220408
IS  - 1879-0844 (Electronic)
IS  - 1388-9842 (Linking)
VI  - 14
IP  - 5
DP  - 2012 May
TI  - Peritoneal dialysis relieves clinical symptoms and is well tolerated in patients 
      with refractory heart failure and chronic kidney disease.
PG  - 530-9
LID - 10.1093/eurjhf/hfs035 [doi]
AB  - AIMS: The aim of the study was to evaluate the efficacy and clinical outcome of 
      peritoneal dialysis (PD) treatment in patients with severe refractory heart 
      failure (HF) and chronic kidney disease (CKD). METHODS AND RESULTS: The PD 
      treatment was performed in 118 patients [49.2% New York Heart Association (NYHA) 
      III and 50.8% NYHA IV] with a mean age of 73.2 +/- 11.4 years as an in-centre-based 
      and intermittent automated PD at least three times per week for 12 h per session 
      and followed up for 1.11 +/- 1.17 years. The functional status of those surviving 
      for 6 months improved (P < 0.0001): 18 (32.1%) of all 60 patients with NYHA IV at 
      baseline died within 6 months, 3 (5.4%) converted to NYHA III, 33 (58.9%) to NYHA 
      II, and 2 (3.6%) to NYHA I. In all 58 patients with NYHA III at baseline, 14 
      (25.0%) died within 6 months, 27 (48.2%) converted to NYHA II, 12 (21.4%) to NYHA 
      I, and 3 (5.4%) showed no improvement. In those surviving for 6 months, fluid 
      overload was significantly reduced as body weight decreased, from 78.7 [95% 
      confidence interval (CI) 75.8-81.7] to 74.7 (71.5-77.9) after 6 months after 
      multiple imputation (P < 0.001). The overall survival rates after 3, 6, and 12 
      months were 77% (95% CI 70-85), 71% (95% CI 62-79), and 55% (95% CI 45-64). In 
      the multivariate analyses, age, diabetes mellitus, serum urea, and brain 
      natriuretic peptide were significantly associated with mortality. The incidence 
      of peritonitis and catheter dysfunction was 0.053 (95% CI 0.014-0.093) and 0.084 
      (95% CI 0.034-0.133), respectively. CONCLUSION: The data suggest that PD is a 
      safe, efficient, and well tolerated therapeutic tool for patients with refractory 
      chronic HF and CKD.
FAU - Koch, Michael
AU  - Koch M
AD  - Nephrologisches Zentrum Mettmann, Gartenstrasse 8, Mettmann, Germany
FAU - Haastert, Burkhard
AU  - Haastert B
FAU - Kohnle, Matthias
AU  - Kohnle M
FAU - Rump, Lars Christian
AU  - Rump LC
FAU - Kelm, Malte
AU  - Kelm M
FAU - Trapp, Rudolf
AU  - Trapp R
FAU - Aker, Sendogan
AU  - Aker S
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20120323
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
CIN - Eur J Heart Fail. 2012 May;14(5):461-3. PMID: 22510421
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Heart Failure/complications/mortality/*therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Natriuretic Peptide, Brain/*blood
MH  - New York
MH  - Peritoneal Dialysis/adverse effects/*methods
MH  - Prospective Studies
MH  - Regression Analysis
MH  - Renal Insufficiency, Chronic/complications/mortality/*therapy
MH  - Severity of Illness Index
MH  - Survival Rate
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2012/03/27 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/03/27 06:00
PHST- 2012/03/27 06:00 [entrez]
PHST- 2012/03/27 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - hfs035 [pii]
AID - 10.1093/eurjhf/hfs035 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 2012 May;14(5):530-9. doi: 10.1093/eurjhf/hfs035. Epub 2012 Mar 
      23.